...
首页> 外文期刊>The Turkish journal of pediatrics. >Long-term follow-up results of patients with adck4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of coq10 supplementation
【24h】

Long-term follow-up results of patients with adck4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of coq10 supplementation

机译:患者患者的长期随访结果已被诊断出在无症状的时期:早期启动COQ10补充的影响

获取原文
           

摘要

Atmaca M, Gülhan B, Atayar E, Karabay Bayaz?t A, Candan C, Ar?c? M, Topalo?lu R, ?zalt?n F. Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation. Turk J Pediatr 2019; 61: 657-663. ADCK4-related glomerulopathy is a recently recognized clinical entity associated with insidious onset in young children and a high potential to progress to chronic kidney disease in adolescents. Early initiation of exogenous coenzyme Q10 (CoQ10) supplementation in the asymptomatic period could be protective on renal functions. In the present study, we aimed to investigate long-term follow-up of patients that we have diagnosed during the asymptomatic period and in whom we started CoQ10 treatment. We analyzed long-term effects of CoQ10 on proteinuria and estimated glomerular filtration rate (eGFR) in this patient population. A total of 8 patients (4 female, 4 male) from 6 different families were included. The mean age at diagnosis and at last visit were 16.8±11.2 years and 20.7±11.7 years, respectively. None of the patients had extrarenal system involvement. At the time of initiation of treatment; median eGFR was 107.8 ml/min/1.73 m2, median proteinuria was 1008 mg/m2/day. After a median follow-up period of 25.3±5.8 months, median proteinuria decreased to 318.5 mg/m2/day (p=0.03) and median eGFR remained stable at 99.6 ml/min/1.73 m2 (p=0.21). Coenzyme Q10 treatment is effective for reducing proteinuria and seems to be renoprotective.
机译:Atmaca M,GülhanB,Atayar E,Karabay Bayaz?T A,Candan C,AR?C? M,Topalo?Lu R,?zalt?n f.患者患者的长期随访结果被诊断出在无症状期间:早期启动CoQ10补充的影响。 Turk J Pediast 2019; 61:657-663。 adck4相关的肾小球疗法是最近公认的临床实体,与幼儿阴险发作相关,以及在青少年慢性肾病的高潜力。早期开始发生外源辅酶Q10(COQ10)在无症状期的补充可能是对肾功能的保护性。在本研究中,我们旨在调查我们在无症状期间诊断的患者的长期随访,以及我们开始COQ10治疗的患者。我们分析了CQ10对蛋白尿和估计肾小球过滤速率(EGFR)的长期影响在该患者群体中。包括来自6名不同家庭的8名患者(4名女性,4只男性)。诊断和最后一次访问的平均年龄分别为16.8±11.2岁,分别为20.7±11.7岁。没有患者没有脱胸肉系统受累。在开始治疗时;中位EGFR为107.8 mL / min / 1.73m2,中位蛋白尿为1008毫克/平方米/天。在25.3±5.8个月的中位随访期后,中位蛋白尿下降至318.5mg / m 2 /天(P = 0.03),中位EGFR保持在99.6ml / min / 1.73m 2(p = 0.21)。辅酶Q10治疗对于还原蛋白尿而有效,似乎是rinoProphotive。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号